View Older Stories View More Recent Stories

Jan 12, 2023 12:56PM New Feature From Topia Allows HR And Global Mobility Professionals To Better Manage Group, Project Team And Bulk Moves
Jan 9, 2023 04:33PM Form SC 13D/A Oyster Point Pharma, Filed by: New Enterprise Associates 14, L.P.
Jan 5, 2023 08:00AM MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Jan 3, 2023 09:00AM Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
Jan 3, 2023 09:00AM Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
Dec 28, 2022 10:00AM GoodLeap Forms Advisory Council with Diverse Leadership and Expertise
Dec 28, 2022 06:00AM Minerva Surgical (UTRS) Prices 146.63M Share Private Placement at $0.205/sh
Dec 27, 2022 05:52PM Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed Partners
Dec 22, 2022 06:13PM Form 4 Arcellx, Inc. For: Dec 20 Filed by: New Enterprise Associates 15, L.P.
Dec 19, 2022 08:00AM Atara Biotherapeutics Announces Changes to Its Board of Directors
Dec 12, 2022 05:25PM Form SC 13D/A Eargo, Inc. Filed by: New Enterprise Associates 15, L.P.
Dec 12, 2022 08:05AM Black Diamond Therapeutics (BDTX) Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
Dec 12, 2022 08:00AM Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
Dec 12, 2022 07:31AM Lumos Pharma, Inc. (LUMO) Announces KOL Review of Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
Dec 12, 2022 07:30AM KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
Dec 12, 2022 07:30AM KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
Dec 12, 2022 07:30AM Celcuity Closes $100 Million Private Placement
Dec 8, 2022 03:01PM IMAS Announces Dr Scott Gottlieb as Keynote Speaker for ACCESS 2023 in Miami Beach
Dec 8, 2022 09:00AM Stride Health Appoints Peter V. Lee, Former Executive Director of Covered California, to Board of Directors
Dec 8, 2022 09:00AM Timescale Announces Appointment of Virginia Liu as Chief Marketing Officer
Dec 7, 2022 04:00PM Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
Nov 29, 2022 04:05PM Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
Nov 29, 2022 04:05PM Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
Nov 28, 2022 12:00AM Escient Pharmaceuticals Announces $120 Million Series C Financing
Nov 22, 2022 04:05PM Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
Nov 22, 2022 04:05PM Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
Nov 21, 2022 01:29PM Form SC 13D/A Oyster Point Pharma, Filed by: New Enterprise Associates 14, L.P.
Nov 18, 2022 05:03PM Form 4 IonQ, Inc. For: Nov 16 Filed by: New Enterprise Associates 15, L.P.
Nov 16, 2022 10:45AM Timescale advances best-in-class price performance for developers with launch of new object storage layer on Amazon S3
Nov 15, 2022 09:00AM Braintrust Tutors Adds Notable Investors Scott Sandell and John Chambers
Nov 15, 2022 09:00AM Braintrust Tutors Adds Notable Investors Scott Sandell and John Chambers
Nov 15, 2022 08:00AM Affordability Education Gap Is No. 1 Barrier to Increasing Independent and Gig Worker Health Coverage Rate, Per New Stride Health Survey
Nov 14, 2022 10:00AM New Wave Foods® Announces Partnership with Restauranteur, Influencer and Television Personality Chef Brian Duffy
Nov 14, 2022 08:00AM ReCode Therapeutics Establishes Scientific Advisory Board
Nov 14, 2022 08:00AM MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
Nov 14, 2022 06:10AM Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
Nov 14, 2022 06:10AM Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
Nov 14, 2022 06:02AM Lumos Pharma (LUMO) Reports Encouraging Interim Results from Two Phase 2 Trials of Oral LUM-201
Nov 14, 2022 06:00AM Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
Nov 14, 2022 06:00AM Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
Nov 13, 2022 10:20PM Rise and fall of crypto exchange FTX
Nov 10, 2022 01:35AM Rise and fall of crypto exchange FTX
Nov 7, 2022 04:05PM Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
Nov 7, 2022 04:05PM Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
Nov 7, 2022 09:15AM Glasswing Ventures Announces Key Additions to Team, Fulfilling its Building Partner Vision
Nov 7, 2022 08:00AM Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022
Nov 4, 2022 04:43PM Form SC 13D/A PhaseBio Pharmaceuticals Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
Nov 4, 2022 08:02AM PMV Pharmaceuticals (PMVP) Appoints Carol Gallagher to its Board
Nov 4, 2022 08:00AM PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
Nov 2, 2022 01:00PM Courtyard Raises $7M in Seed Funding To Redefine Physical Collectibles Ownership Through NFTs
View More Recent Stories View Older Stories